http://jnci.oxfordjournals.org/content/107/11/djv253.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval
         
      </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/107/11/djv253" />
      <meta content="/jnci/107/11/djv253.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval"
            name="DC.Title" />
      <meta content="10.1093/jnci/djv253" name="DC.Identifier" />
      <meta content="2015-11-01" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Denis L. Fontes Jardim" name="DC.Contributor" />
      <meta content="Maria Schwaederle" name="DC.Contributor" />
      <meta content="Caimiao Wei" name="DC.Contributor" />
      <meta content="J. Jack Lee" name="DC.Contributor" />
      <meta content="David S. Hong" name="DC.Contributor" />
      <meta content="Alexander M. Eggermont" name="DC.Contributor" />
      <meta content="Richard L. Schilsky" name="DC.Contributor" />
      <meta content="John Mendelsohn" name="DC.Contributor" />
      <meta content="Vladimir Lazar" name="DC.Contributor" />
      <meta content="Razelle Kurzrock" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Denis L. Fontes Jardim" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Maria Schwaederle" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Caimiao Wei" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="J. Jack Lee" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="David S. Hong" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Alexander M. Eggermont" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Richard L. Schilsky" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="John Mendelsohn" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Vladimir Lazar" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta name="citation_author" content="Razelle Kurzrock" />
      <meta name="citation_author_institution"
            content="&#xA;Affiliations of authors:&#xA;Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM)." />
      <meta content="Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval"
            name="citation_title" />
      <meta content="11/01/2015" name="citation_date" />
      <meta content="107" name="citation_volume" />
      <meta content="11" name="citation_issue" />
      <meta content="djv253" name="citation_firstpage" />
      <meta content="107/11/djv253" name="citation_id" />
      <meta content="107/11/djv253" name="citation_id_from_sass_path" />
      <meta content="jnci;107/11/djv253" name="citation_mjid" />
      <meta content="10.1093/jnci/djv253" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/107/11/djv253.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/107/11/djv253.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/107/11/djv253.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/107/11.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/107/11/djv253"
            name="citation_public_url" />
      <meta content="26378224" name="citation_pmid" />
      <meta name="citation_section" content="Meta-Analysis" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/107/11/djv248.short" rel="prev" />
      <link href="/content/107/11/djv283.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d392359398e1">var callbackToken='537CE571C9E4C46';</script><script type="text/javascript" id="session-d392359398e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:14:37.802-07:00';
            var gSessionId = 'LS0T2PNZum@kQvqfZi3g4g';
            var gAuthzRequired = 'true';
            var gAuthnMethods1 = 'ip';
            var gAuthnMethods2 = 'ip';
            var gAuthnIPs = '18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djv253");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20151101");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F107%2F11%2Fdjv253.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/107/11.toc">
                  <span xmlns="" class="volume-value">Volume 107</span>
                  <span xmlns="" class="issue-value"> Issue 11</span></a></li>
            <li class="last">10.1093/jnci/djv253</li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/107/11/djv253.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view " itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Denis+L.+Fontes+Jardim&amp;sortspec=date&amp;submit=Submit">Denis L. Fontes Jardim</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Maria+Schwaederle&amp;sortspec=date&amp;submit=Submit">Maria Schwaederle</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Caimiao+Wei&amp;sortspec=date&amp;submit=Submit">Caimiao Wei</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=J.+Jack+Lee&amp;sortspec=date&amp;submit=Submit">J. Jack Lee</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-5" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=David+S.+Hong&amp;sortspec=date&amp;submit=Submit">David S. Hong</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-6" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Alexander+M.+Eggermont&amp;sortspec=date&amp;submit=Submit">Alexander M. Eggermont</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-7" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Richard+L.+Schilsky&amp;sortspec=date&amp;submit=Submit">Richard L. Schilsky</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-8" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=John+Mendelsohn&amp;sortspec=date&amp;submit=Submit">John Mendelsohn</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-9" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Vladimir+Lazar&amp;sortspec=date&amp;submit=Submit">Vladimir Lazar</a></span> and 
                     </li>
                     <li class="last" id="contrib-10"><span class="name"><a class="name-search"
                              href="/search?author1=Razelle+Kurzrock&amp;sortspec=date&amp;submit=Submit">Razelle Kurzrock</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address>
                           <strong>Affiliations of authors:</strong>
                           <span class="institution">Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas</span>, <span class="addr-line">Sao Paulo</span>, Brazil (DLFJ); <span class="institution">Department of Clinical Oncology, Hospital Sirio Libanes</span>, <span class="addr-line">Sao Paulo</span>, Brazil (DLFJ); <span class="institution">Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California</span>, San Diego, CA (MS, RK); <span class="institution">Department of Biostatistics, The University of Texas MD Anderson Cancer Center</span>, Houston, TX (CW, JJL); <span class="institution">Department of Investigational Cancer Therapeutics</span> (Phase I Clinical Trials Program), <span class="institution">The University of Texas MD Anderson Cancer Center</span>, Houston, TX (DSH); <span class="institution">Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud</span>, <span class="addr-line">Villejuif</span>, France (AME, VL); <span class="institution">Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France</span> (AME, RLS, JM, VL, RK); <span class="institution">American Society of Clinical Oncology</span>, Alexandria, VA (RLS); <span class="institution">The University of Texas MD Anderson Cancer Center</span>, Houston, TX (JM).
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="corresp" id="corresp-1">
                        <strong>Correspondence to:</strong><br /> Razelle Kurzrock, MD, UC San Diego - Moores Cancer Center, 3855 Health Sciences Drive, MC #0658, La Jolla, CA 92093-0658
                        (e-mail: <span class="em-link"><span class="em-addr">rkurzrock{at}ucsd.edu</span></span>) or Denis L. Fontes Jardim, MD, Department of Clinical Oncology, Hospital Sirio Libanes, Adma Jafet Street, 91, Bela Vista,
                        01308-050, São Paulo, Brazil (e-mail: <span class="em-link"><span class="em-addr">jardimde{at}gmail.com</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2014-12-09"><span class="received-label">Received </span>December 9, 2014.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2015-03-27"><span class="rev-recd-label">Revision received </span>March 27, 2015.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2015-08-17"><span class="accepted-label">Accepted </span>August 17, 2015.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-5" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background:</strong> In order to ascertain the impact of a biomarker-based (personalized) strategy, we compared outcomes between US Food and Drug
                        Administration (FDA)–approved cancer treatments that were studied with and without such a selection rationale.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods:</strong> Anticancer agents newly approved (September 1998 to June 2013) were identified at the Drugs@FDA website. Efficacy, treatment-related
                        mortality, and hazard ratios (HRs) for time-to-event endpoints were analyzed and compared in registration trials for these
                        agents. All statistical tests were two-sided.
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results:</strong> Fifty-eight drugs were included (leading to 57 randomized [32% personalized] and 55 nonrandomized trials [47% personalized],
                        n = 38 104 patients). Trials adopting a personalized strategy more often included targeted (100% vs 65%, <em>P</em> &lt; .001), oral (68% vs 35%, <em>P</em> = .001), and single agents (89% vs 71%, <em>P</em> = .04) and more frequently permitted crossover to experimental treatment (67% vs 28%, <em>P</em> = .009). In randomized registration trials (using a random-effects meta-analysis), personalized therapy arms were associated
                        with higher relative response rate ratios (RRRs, compared with their corresponding control arms) (RRRs = 3.82, 95% confidence
                        interval [CI] = 2.51 to 5.82, vs RRRs = 2.08, 95% CI = 1.76 to 2.47, adjusted <em>P</em> = .03), longer PFS (hazard ratio [HR] = 0.41, 95% CI = 0.33 to 0.51, vs HR = 0.59, 95% CI = 0.53 to 0.65, adjusted <em>P</em> &lt; .001) and a non-statistically significantly longer OS (HR = 0.71, 95% CI = 0.61 to 0.83, vs HR = 0.81, 95% CI = 0.77 to
                        0.85, adjusted <em>P</em> = .07) compared with nonpersonalized trials. Analysis of experimental arms in all 112 registration trials (randomized and
                        nonrandomized) demonstrated that personalized therapy was associated with higher response rate (48%, 95% CI = 42% to 55%,
                        vs 23%, 95% CI = 20% to 27%, <em>P</em> &lt; .001) and longer PFS (median = 8.3, interquartile range [IQR] = 5 vs 5.5 months, IQR = 5, adjusted <em>P</em> = .002) and OS (median = 19.3, IQR = 17 vs 13.5 months, IQR = 8, Adjusted <em>P</em> = .04). A personalized strategy was an independent predictor of better RR, PFS, and OS, as demonstrated by multilinear regression
                        analysis. Treatment-related mortality rate was similar for personalized and nonpersonalized trials.
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions:</strong> A biomarker-based approach was safe and associated with improved efficacy outcomes in FDA-approved anticancer agents.
                     </p>
                  </div>
               </div>
               <p id="p-5">Recently, a deeper understanding of cancer biology has begun to change old paradigms in cancer treatment. Molecular abnormalities
                  are being described as oncogenic or as markers that permit differentiation of normal elements from malignant ones, offering
                  a unique opportunity for target-directed treatment. The US Food and Drug Administration (FDA) has recently granted marketing
                  authorization for the first next-generation genomic sequencer (<a id="xref-ref-1-1" class="xref-bibr" href="#ref-1">1</a>), which, along with rapidly declining costs, is moving genomic diagnostic tests to practice.
               </p>
               <p id="p-6" class="indent">In 2004, only 11 targeted anticancer agents had entered clinical trials (<a id="xref-ref-2-1" class="xref-bibr" href="#ref-2">2</a>), while in 2013 seven new targeted agents received approval by the FDA for cancer treatment, adding to an extensive list
                  (<a id="xref-ref-3-1" class="xref-bibr" href="#ref-3">3</a>). Additionally, many new molecular targeted agents are in development. Strategies to better select patient populations for
                  these new drugs in order to maximize their benefits are in development as well.
               </p>
               <p id="p-7" class="indent">Historically, many drugs were approved without a biomarker for patient selection, including most cytotoxic chemotherapies
                  and some targeted agents. Treatment selection based on biomarkers reflecting biology-specific features that permit differentiation
                  of normal vs malignant cells have brought remarkable advances in oncology. Illustrative examples are imatinib for the treatment
                  of Bcr-Abl–aberrant chronic myelogenous leukemia (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>) and trastuzumab for HER-2 overexpressing breast cancer (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>), which, according to the FDA, started the concept of personalized medicine in cancer (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>). In some cancers, a subgroup of patients whose tumors do not present the biomarker may actually have worse outcomes when
                  treated with targeted agents (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>).
               </p>
               <p id="p-8" class="indent">Despite these examples, the evidence supporting the benefit of a personalized (biomarker-based) approach to cancer treatment
                  is still a matter of debate, with a need for an overview of existing quality data (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>). Therefore, we performed a comprehensive analysis of clinical trials that led to FDA drug approval between September 1998
                  and June 2013. Our analysis included meta-analysis, meta-regression, Wilcoxon test, and weighted least regression analysis
                  applied as appropriate to the 57 randomized trials and the 112 total trials (randomized and nonrandomized). We aimed to compare
                  efficacy outcomes between approved treatments that employed a personalized therapy strategy (matching a molecularly targeted
                  compound with individuals harboring the cognate target) vs those who did not.
               </p>
               <div class="section methods" id="sec-5">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-9" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Methods</h2>
                  <div id="sec-6" class="subsection">
                     <h3>Search Strategy</h3>
                     <p id="p-9">Anticancer agents newly approved between September 1998 (which represents FDA approval of trastuzumab for metastatic breast
                        cancer, starting an era of biomarker-driven therapies) and June 2013 were identified on the FDA website (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>). Agents approved for the treatment of advanced solid and hematologic malignancies were selected for analysis. Agents approved
                        for pediatric cancer, supportive care, loco-regional treatment, hormonal therapies, vaccines, and agents whose basic compound
                        had already been approved before September 1998 were excluded from analysis. The original and most recent package inserts
                        for each agent were reviewed to identify original and posterior indications and clinical trials leading to agent approval.
                        Reports of original trials were obtained through MEDLINE or the ASCO meetings website (<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>) (if the clinical trial was not yet published). Whenever appropriate, we followed the Preferred Reporting Items for Systematic
                        Reviews and Meta-Analysis (PRISMA) statement (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>).
                     </p>
                     <p id="p-10" class="indent">For the purpose of our analysis, personalized therapy and biomarker-based strategy were used interchangeably and carried the
                        same meaning as “matched targeted therapy.” If a targeted agent was used, but it was not matched to the patient population,
                        it was not considered personalized. We defined personalized therapy when a treatment met one of the following criteria: 1)
                        Cognate biomarker was used to select patients for treatment or; 2) No biomarker was used, but at least 50% of patients are
                        known to harbor the cognate biomarker. Homogeneity of biomarkers is generally found only in rare tumor types that are often
                        defined by their specific molecular characteristic. Examples include (but are not limited to) hairy cell leukemia (~100 percent
                        have <em>BRAF</em> mutations) and chronic myelogenous leukemia (~100% carry Bcr-Abl rearrangements) (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>,<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>). In all common solid tumors, any one biomarker is found in only a small subset of patients. A drug was considered personalized
                        if the half maximal inhibitory concentration (IC50) impacted the target at low nM range (&lt;100nM) (for small molecule inhibitors)
                        or if the target was the primary one recognized by an antibody.
                     </p>
                     <p id="p-11">A list of biomarkers accepted for classification of personalized therapy in this study is available online (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv253/-/DC1">Supplementary Table 1</a>, available online).
                     </p>
                  </div>
                  <div id="sec-7" class="subsection">
                     <h3>Study Selection and Data Extraction</h3>
                     <p id="p-12">To be included in the analysis, a trial referred from package insert must have evaluated a drug in an experimental arm, either
                        as a single agent or a combination and reported efficacy endpoints. When the agent was approved in combination, the experimental
                        drug was used for classification. We considered response rate (RR), progression-free survival (PFS) or time to tumor progression
                        (TTP) when PFS was not available, and overall survival (OS) as acceptable efficacy endpoints. Further clinical trials of the
                        same drug were included in the analysis if a new indication for a different tumor type and/or a new combination and/or a new
                        biomarker for patient selection were approved. In these cases, the trials leading to the change in the FDA indication were
                        included as part of the data analysis. Data extraction was conducted independently by two investigators (DLFJ and MS) and
                        any discrepancies were resolved by consensus in frequent meetings in the presence of the principal investigator (RK). All
                        deaths reported by investigators as “possibly,” “probably,” or “definitely” related to treatment were considered toxicity-related
                        deaths.
                     </p>
                     <p id="p-13" class="indent">Responses were recorded according to the response criteria adopted in the trial: for solid tumors, partial and complete responses
                        as per Response Evaluation in Solid Tumors Criteria (RECIST) (<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>) or World Health Organization Criteria (WHO) (<a id="xref-ref-16-1" class="xref-bibr" href="#ref-16">16</a>); for chronic myelogenous leukemia (CML), major cytogenetic responses; for multiple myeloma (MM), partial and complete responses;
                        for acute myelogenous leukemia (AML), complete responses; and for lymphomas, partial and complete responses by WHO criteria.
                        We considered as valid biomarkers results from mutational analysis, cytogenetic or fluorescence in situ hybridization (FISH)
                        tests,or immunohistochemistry assays (for anti-HER2 therapies or for hematological surface markers).
                     </p>
                  </div>
                  <div id="sec-8" class="subsection">
                     <h3>Statistical Analyses</h3>
                     <p id="p-14">All statistical analyses were performed/confirmed by statisticians (CW and JJL). The primary outcome of this meta-analysis
                        was to compare efficacy outcomes (RR, PFS, and OS) and treatment-related mortality between agents developed under a biomarker-based
                        rational (personalized therapy) vs those that did not. For the subgroup of randomized trials in which an experimental arm
                        was compared with a control, we performed a meta-analysis of hazards ratios (HRs) for PFS/TTP and OS and relative response
                        rate ratio (RRR) for personalized trials vs nonpersonalized using a random effects model. The random effects model takes into
                        account of both within-study variation and between-study variation. Relative risk for response ratio was calculated as the
                        response rate in the experimental arm divided by the response rate in the control arms. Randomized trials in which both arms
                        were considered personalized were excluded from this analysis.
                     </p>
                     <p id="p-15" class="indent">For the trials providing only the hazard ratios without 95% confidence intervals (CIs), we used the method by Tierney et al.
                        (<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>) to estimate 95% confidence intervals when a <em>P</em> value for the hazard ratio was available. For the randomized trials with a 1:1 randomization ratio where the hazard ratio
                        was not provided but the number of events and the number of randomized patients was available, we used the method of Tierney
                        et al. (<a id="xref-ref-17-2" class="xref-bibr" href="#ref-17">17</a>) to estimate the HR and then used the method of Altman (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>) to estimate the 95% confidence intervals for the hazard ratios when a <em>P</em> value for the difference between the experimental arm and the control arm was available.
                     </p>
                     <p id="p-16" class="indent">A random effects model based on estimate (log of the response rate, log relative response rate ratios, log hazard ratios)
                        and their standard error was used to pool the estimate across studies using the DerSimonian-Laird method (<a id="xref-ref-19-1" class="xref-bibr" href="#ref-19">19</a>). Random effects meta-regression model (<a id="xref-ref-18-2" class="xref-bibr" href="#ref-18">18</a>,<a id="xref-ref-20-1" class="xref-bibr" href="#ref-20">20</a>) via linear mixed model was used to assess the relationship between the estimates and personalized therapy status, adjusted
                        for other potential confounders/mediators. For the meta-regression models, we assessed these mediators as potential confounders:
                        1) Type of tumor: solid vs hematologic, 2) Previous treatment: yes vs no, 3) Control arm (placebo or BSC vs drug), 4) Allowance
                        of cross-over (for OS only). Heterogeneity between studies was quantified by the between-study variance tau<sup>2</sup> and the Cochran’s Q test and/or the I<sup>2</sup> statistics, which describes the percentage of variation across studies that is because of heterogeneity rather than chance
                        (<a id="xref-ref-21-1" class="xref-bibr" href="#ref-21">21</a>). Studies were classified as presenting low (I<sup>2</sup> ≤ 50%), moderate (I<sup>2</sup> &gt; 50% and ≤ 75%), or high heterogeneity (I<sup>2</sup> ≥75%).
                     </p>
                     <p id="p-17" class="indent">Similarly, for randomized and nonrandomized trials combined, we performed a pooled analysis of the response rates (RRs) for
                        experimental arms using the random effects model and used the meta-regression model to adjust for mediators/confounders: 1)
                        Type of tumor: solid vs hematologic, 2) Study design: randomized vs nonrandomized, 3) Previous chemotherapy: yes vs no, 4)
                        Number of patients evaluable for response in the experimental arm (&gt;178 vs &lt;178). For randomized and nonrandomized trials
                        (single-arm studies) we also compared a pooled analysis of median PFS and OS for experimental arms. To account for differences
                        between studies, we weighted the analysis in proportion to the study sample size using a weighted least-squares analysis.
                        Statistical dispersion was measured by the interquartile range (IQR; the distance between the 75th and the 25th percentile).
                        Assessment of independent samples was done using the Wilcoxon rank-sum test. Multiple linear regression models were fit to
                        assess the association between PFS and OS and several independent variables, in which the variables included the study design
                        (randomized vs nonrandomized), enrichment for molecular targets (personalized vs not personalized), previous systemic therapies
                        (chemo naive vs pretreated), FDA approval date (before the median vs after; the median date was 10/01/2007), number of patients
                        per arm (6–178; 179–839), type of treatment (chemotherapy vs targeted), administration route (oral vs injection), single agent
                        vs combination, and tumor type (solid vs liquid). The final model for PFS analysis contained only the independent variables
                        that were statistically significant in the univariate analysis, while for OS analysis variables with <em>P</em> values of less than .2 were also included. A <em>P</em> value of .05 or less was considered statistically significant. All statistical tests were two-sided.
                     </p>
                     <p id="p-18" class="indent">Statistical analyses were done with R (<a href="http://www.r-project.org/">http://www.r-project.org/</a>) using packages “meta” and “metaphor” and SPSS version 22 (SPSS) software.
                     </p>
                  </div>
               </div>
               <div class="section" id="sec-9">
                  <div class="section-nav"><a href="#sec-5" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-16" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Results</h2>
                  <div id="sec-10" class="subsection">
                     <h3>Search Results</h3>
                     <p id="p-19">We identified 74 FDA-approved drugs for adult cancer treatment indications. After applying previously described criteria,
                        we included 58 approved drugs. Most of the drugs (n = 43, 74%) were classified as targeted agents and approved exclusively
                        for treatment of solid tumors (n = 34, 59%). Review of the package insert from included drugs identified 57 randomized (18
                        [32%] personalized) and 55 nonrandomized trials (26 [47%] personalized), which were the basis of our analysis. A diagram describing
                        the inclusion of trials in the different analyses is available online (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv253/-/DC1">Supplementary Figure 1</a>, available online). These trials enrolled a total of 38 104 patients (30 701, randomized; 7403, nonrandomized trials) (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv253/-/DC1">Supplementary Tables 2 and 3</a>, available online).
                     </p>
                  </div>
                  <div id="sec-11" class="subsection">
                     <h3>Characteristics of Trials</h3>
                     <p id="p-20">Personalized trials accrued a median number of 152 patients (range = 7–533) per experimental arm compared with 204.5 (33–862)
                        for nonpersonalized trials (<em>P</em> = .29). Agents that were tested with a personalized strategy were all considered to be targeted agents (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>). In contrast, only 65% were classified as targeted when a nonpersonalized approach was employed (<em>P</em> &lt; .001). Statistically significant differences between personalized vs nonpersonalized trials were also detected regarding
                        increased use of oral (68% vs 35%, <em>P</em> = .001) and single agents (89% vs 71%, <em>P</em> = .04), respectively. Allowance for crossover to the experimental arm was higher in randomized trials with personalized treatments
                        in comparison with nonpersonalized (67% vs 28%, <em>P</em> = .009). There was a suggestion for nonpersonalized trials to be more frequently randomized, although with no statistical
                        significance (<em>P</em> = .12) (<a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>; <a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv253/-/DC1">Supplementary Table 4</a>, available online).
                     </p>
                     <div id="T1" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="djv253/T1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="djv253/T1.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 1.</span> 
                           <p id="p-21" class="first-child">Comparison of the main characteristics between personalized and nonpersonalized trials</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-12" class="subsection">
                     <h3>Meta-Analysis of Relative Benefits of Personalized Therapy in Randomized Registration Trials</h3>
                     <p id="p-24">We performed a meta-analysis of relative benefits in RR, PFS, and OS between the experimental arms and their corresponding
                        control arms for randomized registration trials (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>). Fifty-one studies were included in the RRR and PFS analysis. The RRR analysis showed a higher likelihood of response with
                        a personalized compared with nonpersonalized strategy (RRR = 3.82, 95% CI = 2.51 to 5.82, vs 2.08, 95% CI = 1.76 to 2.47,
                        <em>P</em> = .009) (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1A</a>). After adjusting for other mediators in the meta-regression model, personalized therapy remained as a statistically significant
                        predictor of RRR (adjusted <em>P</em> = .03) (<a id="xref-table-wrap-2-2" class="xref-table" href="#T2">Table 2</a>).
                     </p>
                     <div id="T2" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="djv253/T2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="djv253/T2.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 2.</span> 
                           <p id="p-25" class="first-child">Meta-analysis (univariate and multivariate) using random effects model according to trial characteristics (including personalized
                              vs non-personalized drugs) in randomized registration trials
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F1" class="fig pos-float type-figure  odd">
                        <div class="fig-inline"><a href="djv253/F1.expansion.html"><img alt="Figure 1." src="djv253/F1/graphic-1.small.gif" /></a><a href="djv253/F1.expansion.html"><img alt="Figure 1." src="djv253/F1/graphic-2.small.gif" /></a><a href="djv253/F1.expansion.html"><img alt="Figure 1." src="djv253/F1/graphic-3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="djv253/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="djv253/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/107/11/djv253/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 1.</span> 
                           <p id="p-28" class="first-child">Forest-plot representing the relative response rate ratio <strong>(A)</strong>, hazard ratios for progression-free survival (PFS) <strong>(B)</strong>, and overall survival (OS) <strong>(C)</strong> between experimental and control arms by personalized therapy status in randomized registration trials. Studies are labeled
                              by first author’s last name, and references were numbered according to supplementary references. In <strong>(A)</strong>, RRR is shown and lines to the <strong>right of the vertical line</strong> indicate improvement in the experimental arm. In <strong>(B and C)</strong>, the <strong>plots</strong> show hazard ratios (HRs) and, therefore, <strong>lines to the left of the vertical line</strong> indicate improvement (ie, lower HR for PFS or OS) for the experimental arm. <em>P</em> values were tested for subgroup differences (chi-square) and are two-sided. df = degree of freedom; Q = Cochran’s Q test.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-29" class="indent">In randomized trials, the estimated hazard ratio for PFS of experimental compared with control arms was 0.41 (95% CI = 0.33
                        to 0.51) for personalized compared with 0.59 (95% CI = 0.53 to 0.65) for nonpersonalized studies (nonadjusted <em>P</em> = .004), indicating a greater improvement in PFS in the personalized approach (<a id="xref-fig-1-2" class="xref-fig" href="#F1">Figure 1B</a>), which was confirmed in the meta-regression model (adjusted <em>P</em> &lt; .001). In RRR and PFS analysis, heterogeneity between studies within personalized and nonpersonalized cohorts was classified
                        as high (I<sup>2</sup> &gt; 75%).
                     </p>
                     <p id="p-30" class="indent">For the 46 randomized trials where the hazard ratio of OS and corresponding 95% confidence interval were provided, the estimated
                        hazard ratios for OS were 0.71 (95% CI = 0.61 to 0.83) for personalized compared with 0.81 (95% CI = 0.77 to 0.85) for nonpersonalized
                        studies. This difference was not statistically significant (<a id="xref-fig-1-3" class="xref-fig" href="#F1">Figure 1C</a>). With adjustment for other mediators, including crossover to experimental arm and type of tumor (solid vs hematologic),
                        personalized therapy was associated with slightly lower hazard ratios for OS (adjusted <em>P</em> = .07). Heterogeneity between studies within personalized and nonpersonalized cohorts was classified as moderate (50% &lt; I<sup>2</sup> ≤ 75%).
                     </p>
                     <p id="p-31" class="indent">An exploratory univariate analysis suggested, amongst biomarker-driven trials, response rate was improved for trials adopting
                        biomarkers such as immunohistochemistry or FISH vs mutation analysis, while for RRR the opposite was true (<a href="http://jnci.oxfordjournals.org/lookup/suppl/doi:10.1093/jnci/djv253/-/DC1">Supplementary Table 5</a>, available online). The number of studies in these analyses is small and might be subject to bias, and this statistical significance
                        did not hold in multivariate analysis (results not shown). In addition, no statistically significant differences were observed
                        for PFS or OS in the same stratified analysis.
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Personalized Therapy and Response Rate in All Trials</h3>
                     <p id="p-32">Of the 111 trials (both randomized and nonrandomized) reporting responses, the RR in the experimental arm was statistically
                        significantly higher in the personalized trials compared with nonpersonalized trials (random effect model meta-analysis) (RR
                        = 48%, 95% CI = 42% to 55%, vs RR = 23%, 95% CI = 20% to 27%, respectively, <em>P</em> &lt; .001), even within randomized and nonrandomized subgroups (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). We also observed higher RRs in nonrandomized vs randomized studies (40% vs 25%, <em>P</em> &lt; .001), treatment-naïve vs pretreated population (40% vs 29%, <em>P</em> = .01), trials with a smaller number of patients (38% vs 27%, <em>P</em> = .04), and hematologic vs solid tumors (46% vs 24%, <em>P</em> &lt; .001). After adjustments for statistically significant factors, personalized therapy remained a statistically significant
                        determinant of response rate in experimental arms of registration trials, with an adjusted relative risk ratio of 2.22 (95%
                        CI = 1.64 to 3.02) when compared with nonpersonalized arms (<em>P</em> &lt; .001). In addition, trials involving hematologic tumors and a treatment-naïve population were also statistically significantly
                        associated with higher RR in the meta-regression model.
                     </p>
                     <div id="T3" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="djv253/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="djv253/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3.</span> 
                           <p id="p-33" class="first-child">Meta-analysis (univariate and multivariate) using random effects model comparing the response rate in the experimental arms
                              between personalized and nonpersonalized registration trials. Unlike <a id="xref-table-wrap-2-3" class="xref-table" href="#T2">Table 2</a>, data from both randomized and nonrandomized trials were included
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Personalized Therapy and Progression-Free Survival</h3>
                     <p id="p-37">Of the 112 trials included in our analysis, 90 (80%) reported PFS as an efficacy outcome. The median PFS for the experimental
                        arm of these trials was 6.2 months (interquartile range [IQR] = 5). For 13 trials, the data were not available, and for nine
                        the median PFS was “not reached” (all personalized). These trials were excluded from the analysis. Experimental arms that
                        included a personalized therapy had a median PFS of 8.3 months (IQR = 5) vs 5.5 months (IQR = 5) for nonpersonalized therapy
                        (<em>P</em> &lt; .001) (<a id="xref-table-wrap-4-1" class="xref-table" href="#T4">Table 4</a>). In addition, treatment-naïve population was also a statistically significant factor associated with longer PFS in the univariate
                        analysis (<em>P</em> = .004), but only the adoption of a personalized strategy for treatment selection in a trial was confirmed as an independent
                        predictor of longer PFS in the multilinear regression analysis (<em>P</em> = .002).
                     </p>
                     <div id="T4" class="table pos-float">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="djv253/T4.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="djv253/T4.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 4.</span> 
                           <p id="p-38" class="first-child">Survival outcomes of patients on randomized and nonrandomized registration trials of anticancer agents from 09/1998 to 06/2013</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-15" class="subsection">
                     <h3>Personalized Therapy and Overall Survival</h3>
                     <p id="p-42">Of the 112 trials, the median OS of the experimental arm was reported in 60 (54%). Median OS in these trials was 14.2 months
                        (IQR = 9). For 22 trials, the data were not available, and for 30 trials the median OS was not reached (23 of them were personalized).
                        Trials employing a personalized therapy strategy described a statistically significant longer OS (19.3 months, IQR = 17) compared
                        with nonpersonalized therapy (13.5 months, IQR = 8, <em>P</em> = .01) (<a id="xref-table-wrap-4-2" class="xref-table" href="#T4">Table 4</a>). In the multilinear regression model, personalized therapy remained as the only factor selected as an independent predictor
                        of survival (<em>P</em> = .04).
                     </p>
                     <p id="p-43" class="indent">Eighty-one trials (72%) had information about treatment-related deaths. Treatment-related mortality was 1.6 percent (95% CI
                        = 1% to 2.4%) for personalized vs 1.4 percent (95% CI = 1% to 2%) for nonpersonalized trials, which was not statistically
                        different (<em>P</em> = .74).
                     </p>
                  </div>
               </div>
               <div class="section" id="sec-16">
                  <div class="section-nav"><a href="#sec-9" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-17" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Discussion</h2>
                  <p id="p-44">Our comprehensive review of trials leading to FDA approval of oncology drugs included a meta-analysis, in which the adoption
                     of a biomarker-based (personalized) approach was an independent factor associated with a higher RRR (<em>P</em> = .03) and prolongation of PFS (<em>P</em> &lt; .001), and a suggestion towards longer OS, although not statistically significant (<em>P</em> = .07) compared with a nonpersonalized therapy strategy in randomized trials. Our results demonstrated a relative increase
                     in median PFS for the use of personalized vs nonpersonalized agents against their respective control arms in randomized trials
                     and a relative increase in median OS. In addition, a systematic review of all registration trials (both randomized and nonrandomized)
                     confirmed that personalized therapy was statistically significantly and independently associated with higher RR (<em>P</em> &lt; .001) and longer PFS (<em>P</em> = .002) and OS (<em>P</em> = .04), even after adjustments for confounding variables.
                  </p>
                  <p id="p-45" class="indent">Personalized therapy trials also had treatment-related mortality rates similar to nonpersonalized trials. The toxicity-mortality
                     rate described herein is similar to that in a previous report of phase I trials that evaluated anticancer drugs studied by
                     the National Cancer Institute (mortality that was possibly drug related = 0.49%) (<a id="xref-ref-22-1" class="xref-bibr" href="#ref-22">22</a>,<a id="xref-ref-23-1" class="xref-bibr" href="#ref-23">23</a>). Other studies have also shown that safety and dose in early trials is highly predictive for later trials, possibly accounting
                     in part for the low drug-related death rates in our registration trials (<a id="xref-ref-24-1" class="xref-bibr" href="#ref-24">24</a>).
                  </p>
                  <p id="p-46" class="indent">In our study, registration trials for FDA approval of new anticancer agents included 57 randomized and 55 nonrandomized trials
                     (38 104 patients). A meta-analysis of hazard ratios for time-to-event endpoints using the random-effects model is the most
                     acceptable statistical approach to compare the efficacy of two different strategies amongst heterogeneous trials. However,
                     this type of analysis was not possible (for PFS and OS) in most of our nonrandomized trials because the confidence intervals
                     or the variances for the medians were not reported. Therefore, the meta-analysis was applied to the randomized studies for
                     the hazard ratios for PFS/OS and RRR and to all studies for response rates (because the latter data were fully available in
                     both randomized and nonrandomized studies). Importantly, in our group of studies personalized trials were more often nonrandomized
                     (59% vs 43% for nonpersonalized), although not statistically significant (<em>P</em> = .12). Because the decision to not randomize a trial is often based on having observed high response rates in earlier clinical
                     trials, the trend to nonrandomization, and hence exclusion of a higher number of trials in the personalized group, could have
                     attenuated the effects observed in the meta-analysis (<a id="xref-ref-25-1" class="xref-bibr" href="#ref-25">25</a>).
                  </p>
                  <p id="p-47" class="indent">In order to include both randomized and nonrandomized studies in PFS/OS analysis, we performed a weighted data analysis of
                     the 112 registration trials. Although using median survival times at a particular point in time (rather than hazard ratios
                     between experimental and control arms) has intrinsic limitations (<a id="xref-ref-26-1" class="xref-bibr" href="#ref-26">26</a>), the advantage of this approach was that substantially more trials were included, as we were no longer limited to randomized
                     trials. However, inclusion of the nonrandomized trials may lead to unrecognized bias arising from different populations being
                     compared without the reference of a control group. In addition, the weighted analysis can also introduce a bias, because some
                     authors have shown that personalized trials tend to be smaller (<a id="xref-ref-27-1" class="xref-bibr" href="#ref-27">27</a>), perhaps because the hypothesized response rates are higher and some molecular subtypes of cancers are rare. We also observed
                     a smaller number of patients on experimental arms of personalized trials vs nonpersonalized (median = 152 vs 204 patients),
                     though this difference was not statistically significant (<em>P</em> = .29). Finally, there was a statistically significantly higher number of studies not reaching a median PFS/OS within the
                     personalized category (<em>P</em> &lt; .001). Because no median was available, we excluded these studies, though these trials might be expected to have the longest
                     PFS/OS. This approach might have biased the analysis against personalized trials. Despite these factors, our results revealed
                     better outcomes with a personalized strategy. All personalized drugs were classified as targeted agents, and no cytotoxic
                     agents were considered personalized. This finding may reflect the fact that the precise mechanism of action of cytotoxic agents
                     and the biomarkers for them have only recently been explored (<a id="xref-ref-28-1" class="xref-bibr" href="#ref-28">28</a>,<a id="xref-ref-29-1" class="xref-bibr" href="#ref-29">29</a>).
                  </p>
                  <p id="p-48" class="indent">The hazard ratio for overall survival in the randomized trials was better with personalized treatment, although this did not
                     reach statistical significance in multivariate analysis (<em>P</em> = 0.07). A possible explanation for this finding was a statistically significantly higher crossover to the experimental arm
                     in personalized trials. In addition, the small number of randomized trials (evaluable = 46 in total with 13 being personalized)
                     may have precluded definitive associations with survival. Successful drugs developed with a strong biologic rationale, including
                     a biomarker for treatment selection, often demonstrate higher antitumor activity in early trials (<a id="xref-ref-30-1" class="xref-bibr" href="#ref-30">30</a>,<a id="xref-ref-31-1" class="xref-bibr" href="#ref-31">31</a>). This is a plausible reason for the majority of personalized trials allowing crossover to the experimental arm, confounding
                     the assessment of OS (<a id="xref-ref-32-1" class="xref-bibr" href="#ref-32">32–35</a>). When both randomized and nonrandomized trials were included in the survival multilinear regression analysis, personalized
                     therapy was the only independent factor associated with longer OS. It is conceivable that a personalized approach might show
                     even greater impact earlier in the disease course (<a id="xref-ref-36-1" class="xref-bibr" href="#ref-36">36</a>).
                  </p>
                  <p id="p-49" class="indent">Our study is not the first to demonstrate the benefit of a personalized treatment approach. Von Hoff et al. (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>) showed that treatment matched to profiled tumors rendered a statistically significantly longer PFS when compared with the
                     patient’s previous PFS on a nonselected treatment. Other studies with a similar design (using patients as their own controls)
                     suggested that a personalized approach was feasible and more effective than using a nonselected treatment (<a id="xref-ref-38-1" class="xref-bibr" href="#ref-38">38–40</a>) Indeed, in melanoma, the median PFS on personalized phase I therapy was longer than the PFS for these patients on their
                     prior first-line standard treatment (<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>). Many of these studies were conducted when few biomarkers for treatment selection were available or validated; thus, it
                     might be expected that salutary effects would increase as more potent “omics” diagnostic technology becomes available.
                  </p>
                  <p id="p-50" class="indent">Previous evidence to support a personalized treatment approach was also shown by intertrial comparisons. Janku et al. analyzed
                     phase II trials in non–small cell lung cancer and demonstrated that treatment arms enriched for patients with molecular targets
                     had a higher median RR (48.8% vs 9.7%, <em>P</em> = .005) and longer median PFS (6 vs 2.8 months, <em>P</em> = .005) and OS (11.3 vs 7.5 months, <em>P</em> = .05) as compared with those of patients not selected with a biomarker-driven rational (<a id="xref-ref-41-1" class="xref-bibr" href="#ref-41">41</a>). In multivariate analysis, only studies enriched for patients with molecular targets or including drugs that eventually
                     gained FDA approval were associated with better outcomes. A substantial prolongation of PFS and OS was also previously reported
                     for some FDA-approved agents in a range of different solid tumors when a targeted population was selected by a biomarker (<a id="xref-ref-27-2" class="xref-bibr" href="#ref-27">27</a>).
                  </p>
                  <p id="p-51" class="indent">Our study has some limitations. First, we only included successful FDA-approved agents. Certainly, some cancer drugs, biomarkers,
                     and/or personalized or nonpersonalized approaches were tested and failed during drug development (<a id="xref-ref-42-1" class="xref-bibr" href="#ref-42">42</a>), possibly affecting the generalizability of our findings. Second, our study did not restrict itself to a tumor type or a
                     single biomarker. There was a wide variation in the nature and number of tests selected for each personalized therapy, and
                     not all biomarkers were associated with a validated approved companion diagnosis. It is possible that the personalized strategy
                     has differential benefits depending on histology or biological context. However, the fact that we analyzed all registration
                     trials in the time period also supports the validity of the observations across cancer types and genomic biomarkers. Another
                     limitation was our inclusion of an analysis of nonrandomized trials in addition to our analysis of randomized trials. Both
                     analyses produced consistent results, but nonrandomized trials may lead to unidentifiable bias arising from different patient
                     populations being compared. Because many personalized trials were nonrandomized, it was nevertheless felt to be important
                     to include this additional analysis of all studies. Finally, all included personalized therapies were targeted agents, so
                     we cannot extend our findings to personalization of hormonal agents, cytotoxic drugs, or immunotherapies.
                  </p>
                  <p id="p-52" class="indent">Our data indicate that personalized therapy, defined as biomarker-based targeted treatment in the context of drugs that reached
                     FDA approval, is associated with increased clinical benefit across tumor types and markers, as demonstrated by substantially
                     higher response rates, longer time to disease progression, and longer survival, as well as improved relative response rates
                     and hazard ratios for PFS in randomized trials, with no compromise in treatment-related mortality.
                  </p>
               </div>
               <div class="section" id="sec-17">
                  <div class="section-nav"><a href="#sec-16" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#notes-1" title="Notes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2 class="">Funding</h2>
                  <p id="p-53">Funded in part by the Joan and Irwin Jacobs Fund, My Answer To Cancer philanthropic fund and Foundation Medicine granted to
                     Dr. Razelle Kurzrock.
                  </p>
               </div>
               <div class="section notes" id="notes-1">
                  <div class="section-nav"><a href="#sec-17" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Notes</h2>
                  <p id="p-54">The study funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing
                     of the manuscript; nor the decision to submit the manuscript for publication.
                  </p>
                  <p id="p-55">Author contributions: DLFJ, MS, and RK designed the study and supervised its conduct and the data analysis. All authors were
                     involved in interpretation of data. MS did the initial statistical analysis, and the approaches and results were verified
                     and complemented by CW and JJL. All authors had the opportunity to review the analysis plan and outcomes, critically reviewed
                     the manuscript drafts, approved the final version, and made the decision to submit for publication.
                  </p>
                  <p id="p-56">The authors have no conflicts of interest to declare.</p>
               </div>
               <ul class="copyright-statement">
                  <li class="fn" id="copyright-statement-1">© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#notes-1" title="Notes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2 class="">References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><a class="rev-xref-ref" href="#xref-ref-1-1" title="View reference 1. in text"
                           id="ref-1">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.1"
                             data-doi="10.1056/NEJMp1314561">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Collins</span>
                                       <span class="cit-name-given-names">FS</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hamburg</span>
                                       <span class="cit-name-given-names">MA</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">First FDA authorization for next-generation sequencer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">369</span>
                                 <span class="cit-issue">(25)</span>:<span class="cit-fpage">2369</span>–<span class="cit-lpage">2371</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMp1314561&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=24251383&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000328586000003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><a class="rev-xref-ref" href="#xref-ref-2-1" title="View reference 2. in text"
                           id="ref-2">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.2"
                             data-doi="10.1038/nature03095">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Sawyers</span>
                                       <span class="cit-name-given-names">C</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Targeted cancer therapy</span>. <abbr class="cit-jnl-abbrev">Nature</abbr>. <span class="cit-pub-date">2004</span>;<span class="cit-vol">432</span>
                                 <span class="cit-issue">(7015)</span>:<span class="cit-fpage">294</span>–<span class="cit-lpage">297</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/nature03095&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15549090&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000225161400038&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><a class="rev-xref-ref" href="#xref-ref-3-1" title="View reference 3. in text"
                           id="ref-3">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.3">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">National Cancer Institute: Targeted cancer therapies</span>. <span class="cit-article-title">Fact Sheet</span>. <a href="http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted">http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted</a> Accessed November 25, 2013.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text"
                           id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.4"
                             data-doi="10.1056/NEJMoa011573">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kantarjian</span>
                                       <span class="cit-name-given-names">H</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Sawyers</span>
                                       <span class="cit-name-given-names">C</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hochhaus</span>
                                       <span class="cit-name-given-names">A</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2002</span>;<span class="cit-vol">346</span>
                                 <span class="cit-issue">(9)</span>:<span class="cit-fpage">645</span>–<span class="cit-lpage">652</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa011573&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11870241&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000174062800002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.5"
                             data-doi="10.1056/NEJM200103153441101">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Slamon</span>
                                       <span class="cit-name-given-names">DJ</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Leyland-Jones</span>
                                       <span class="cit-name-given-names">B</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Shak</span>
                                       <span class="cit-name-given-names">S</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2001</span>;<span class="cit-vol">344</span>
                                 <span class="cit-issue">(11)</span>:<span class="cit-fpage">783</span>–<span class="cit-lpage">792</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200103153441101&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11248153&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167440400001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.6">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Food and Drug Administration Consumers Update</span>. <a href="http://www.fda.gov/forconsumers/consumerupdates/ucm407328.htm">http://www.fda.gov/forconsumers/consumerupdates/ucm407328.htm</a> - Herceptin.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.7"
                             data-doi="10.1200/JCO.2009.27.4860">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Douillard</span>
                                       <span class="cit-name-given-names">JY</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Siena</span>
                                       <span class="cit-name-given-names">S</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Cassidy</span>
                                       <span class="cit-name-given-names">J</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4
                                    alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>
                                 <span class="cit-issue">(31)</span>:<span class="cit-fpage">4697</span>–<span class="cit-lpage">4705</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=28/31/4697"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.8"
                             data-doi="10.1056/NEJMoa1208958">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Callahan</span>
                                       <span class="cit-name-given-names">MK</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Rampal</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Harding</span>
                                       <span class="cit-name-given-names">JJ</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Progression of RAS-mutant leukemia during RAF inhibitor treatment</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">367</span>
                                 <span class="cit-issue">(24)</span>:<span class="cit-fpage">2316</span>–<span class="cit-lpage">2321</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1208958&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=23134356&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.9"
                             data-doi="10.1158/1078-0432.CCR-13-0753">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Jurgensmeier</span>
                                       <span class="cit-name-given-names">JM</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Eder</span>
                                       <span class="cit-name-given-names">JP</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Herbst</span>
                                       <span class="cit-name-given-names">RS</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2014</span>;<span class="cit-vol">20</span>
                                 <span class="cit-issue">(17)</span>:<span class="cit-fpage">4425</span>–<span class="cit-lpage">4435</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=20/17/4425"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.10">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Food and Drug Administration (FDA)</span>. Drugs @FDA. <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/</a> Accessed July 30, 2014.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.11">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">American Society of Clinical Oncology meeting website</span>. <a href="http://meetinglibrary.asco.org/abstracts">http://meetinglibrary.asco.org/abstracts</a> Accessed August 03, 2014.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.12"
                             data-doi="10.7326/0003-4819-151-4-200908180-00136">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Liberati</span>
                                       <span class="cit-name-given-names">A</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Altman</span>
                                       <span class="cit-name-given-names">DG</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Tetzlaff</span>
                                       <span class="cit-name-given-names">J</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:
                                    explanation and elaboration</span>. <abbr class="cit-jnl-abbrev">Ann Intern Med</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">151</span>
                                 <span class="cit-issue">(4)</span>:<span class="cit-fpage">W65</span>–<span class="cit-lpage">W94</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-151-4-200908180-00136&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=19622512&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000269038900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.13"
                             data-doi="10.1016/j.blre.2014.06.003">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Grever</span>
                                       <span class="cit-name-given-names">MR</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Blachly</span>
                                       <span class="cit-name-given-names">JS</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Andritsos</span>
                                       <span class="cit-name-given-names">LA</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Hairy cell leukemia: Update on molecular profiling and therapeutic advances</span>. <abbr class="cit-jnl-abbrev">Blood Rev</abbr>
                                 <span class="cit-pub-date">2014</span>;<span class="cit-vol">28</span>
                                 <span class="cit-issue">(5)</span>:<span class="cit-fpage">197</span>–<span class="cit-lpage">203</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/j.blre.2014.06.003&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=25110197&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.14"
                             data-doi="10.1182/blood-2008-07-077958">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Druker</span>
                                       <span class="cit-name-given-names">BJ</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Translation of the Philadelphia chromosome into therapy for CML</span>. <abbr class="cit-jnl-abbrev">Blood</abbr>. <span class="cit-pub-date">2008</span>;<span class="cit-vol">112</span>
                                 <span class="cit-issue">(13)</span>:<span class="cit-fpage">4808</span>–<span class="cit-lpage">4817</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bloodjournal&amp;resid=112/13/4808"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.15"
                             data-doi="10.1093/jnci/92.3.205">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Therasse</span>
                                       <span class="cit-name-given-names">P</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Arbuck</span>
                                       <span class="cit-name-given-names">SG</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Eisenhauer</span>
                                       <span class="cit-name-given-names">EA</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of
                                    Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst</abbr>. <span class="cit-pub-date">2000</span>;<span class="cit-vol">92</span>
                                 <span class="cit-issue">(3)</span>:<span class="cit-fpage">205</span>–<span class="cit-lpage">216</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=92/3/205"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><a class="rev-xref-ref" href="#xref-ref-16-1" title="View reference 16. in text"
                           id="ref-16">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.16"
                             data-doi="10.1002/1097-0142(19810101)47:1&lt;207::AID-CNCR2820470134&gt;3.0.CO;2-6">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Miller</span>
                                       <span class="cit-name-given-names">AB</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hoogstraten</span>
                                       <span class="cit-name-given-names">B</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Staquet</span>
                                       <span class="cit-name-given-names">M</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Reporting results of cancer treatment</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr>. <span class="cit-pub-date">1981</span>;<span class="cit-vol">47</span>
                                 <span class="cit-issue">(1)</span>:<span class="cit-fpage">207</span>–<span class="cit-lpage">214</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19810101)47:1%3C207::AID-CNCR2820470134%3E3.0.CO;2-6&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7459811&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1981KY59900033&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.17"
                             data-doi="10.1186/1745-6215-8-16">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Tierney</span>
                                       <span class="cit-name-given-names">JF</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Stewart</span>
                                       <span class="cit-name-given-names">LA</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Ghersi</span>
                                       <span class="cit-name-given-names">D</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Practical methods for incorporating summary time-to-event data into meta-analysis</span>. <abbr class="cit-jnl-abbrev">Trials</abbr>. <span class="cit-pub-date">2007</span>;<span class="cit-vol">8</span>:<span class="cit-fpage">16</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1745-6215-8-16&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17555582&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.18"
                             data-doi="10.1136/bmj.d2304">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Altman</span>
                                       <span class="cit-name-given-names">DG</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Bland</span>
                                       <span class="cit-name-given-names">JM</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">How to obtain the P value from a confidence interval</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">343</span>:<span class="cit-fpage">d2304</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=343/aug08_1/d2304"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><a class="rev-xref-ref" href="#xref-ref-19-1" title="View reference 19. in text"
                           id="ref-19">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.19"
                             data-doi="10.1016/0197-2456(86)90046-2">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">DerSimonian</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Laird</span>
                                       <span class="cit-name-given-names">N</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Meta-analysis in clinical trials</span>. <abbr class="cit-jnl-abbrev">Control Clin Trials</abbr>. <span class="cit-pub-date">1986</span>;<span class="cit-vol">7</span>
                                 <span class="cit-issue">(3)</span>:<span class="cit-fpage">177</span>–<span class="cit-lpage">188</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0197-2456(86)90046-2&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3802833&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F013900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><a class="rev-xref-ref" href="#xref-ref-20-1" title="View reference 20. in text"
                           id="ref-20">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.20">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Viechtbauer</span>
                                       <span class="cit-name-given-names">W</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Conducting Meta-Analyses in R with the Metafor Package</span>. <abbr class="cit-jnl-abbrev">J Stat Software</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">36</span>:<span class="cit-fpage">1</span>–<span class="cit-lpage">48</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><a class="rev-xref-ref" href="#xref-ref-21-1" title="View reference 21. in text"
                           id="ref-21">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.21"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Higgins</span>
                                       <span class="cit-name-given-names">JP</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Thompson</span>
                                       <span class="cit-name-given-names">SG</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Quantifying heterogeneity in a meta-analysis</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr>. <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>
                                 <span class="cit-issue">(11)</span>:<span class="cit-fpage">1539</span>–<span class="cit-lpage">1558</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><a class="rev-xref-ref" href="#xref-ref-22-1" title="View reference 22. in text"
                           id="ref-22">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.22"
                             data-doi="10.1056/NEJMsa042220">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Horstmann</span>
                                       <span class="cit-name-given-names">E</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">McCabe</span>
                                       <span class="cit-name-given-names">MS</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Grochow</span>
                                       <span class="cit-name-given-names">L</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Risks and benefits of phase 1 oncology trials, 1991 through 2002</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2005</span>;<span class="cit-vol">352</span>
                                 <span class="cit-issue">(9)</span>:<span class="cit-fpage">895</span>–<span class="cit-lpage">904</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMsa042220&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15745980&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227310700008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><a class="rev-xref-ref" href="#xref-ref-23-1" title="View reference 23. in text"
                           id="ref-23">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.23"
                             data-doi="10.1056/NEJMe058007">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kurzrock</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Benjamin</span>
                                       <span class="cit-name-given-names">RS</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">Risks and benefits of phase 1 oncology trials, revisited</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2005</span>;<span class="cit-vol">352</span>
                                 <span class="cit-issue">(9)</span>:<span class="cit-fpage">930</span>–<span class="cit-lpage">932</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMe058007&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15745986&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227310700015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><a class="rev-xref-ref" href="#xref-ref-24-1" title="View reference 24. in text"
                           id="ref-24">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.24"
                             data-doi="10.1158/1078-0432.CCR-13-2103">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Jardim</span>
                                       <span class="cit-name-given-names">DL</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hess</span>
                                       <span class="cit-name-given-names">KR</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Lorusso</span>
                                       <span class="cit-name-given-names">P</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2014</span>;<span class="cit-vol">20</span>
                                 <span class="cit-issue">(2)</span>:<span class="cit-fpage">281</span>–<span class="cit-lpage">288</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=20/2/281"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">25.</span><a class="rev-xref-ref" href="#xref-ref-25-1" title="View reference 25. in text"
                           id="ref-25">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.25"
                             data-doi="10.1200/JCO.2009.23.6018">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Tsimberidou</span>
                                       <span class="cit-name-given-names">AM</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Braiteh</span>
                                       <span class="cit-name-given-names">F</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Stewart</span>
                                       <span class="cit-name-given-names">DJ</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2009</span>;<span class="cit-vol">27</span>
                                 <span class="cit-issue">(36)</span>:<span class="cit-fpage">6243</span>–<span class="cit-lpage">6250</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=27/36/6243"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">26.</span><a class="rev-xref-ref" href="#xref-ref-26-1" title="View reference 26. in text"
                           id="ref-26">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.26">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Michiels</span>
                                       <span class="cit-name-given-names">S</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Piedbois</span>
                                       <span class="cit-name-given-names">P</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Burdett</span>
                                       <span class="cit-name-given-names">S</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Meta-analysis when only the median survival times are known: a comparison with individual patient data results</span>. <abbr class="cit-jnl-abbrev">Int J Technol Assess Health Care</abbr>. <span class="cit-pub-date">2005</span>;<span class="cit-vol">21</span>
                                 <span class="cit-issue">(1)</span>:<span class="cit-fpage">119</span>–<span class="cit-lpage">125</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15736523&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227073800015&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">27.</span><a class="rev-xref-ref" href="#xref-ref-27-1" title="View reference 27. in text"
                           id="ref-27">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.27"
                             data-doi="10.1200/JCO.2011.35.2393">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Amir</span>
                                       <span class="cit-name-given-names">E</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Seruga</span>
                                       <span class="cit-name-given-names">B</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Martinez-Lopez</span>
                                       <span class="cit-name-given-names">J</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2011</span>;<span class="cit-vol">29</span>
                                 <span class="cit-issue">(18)</span>:<span class="cit-fpage">2543</span>–<span class="cit-lpage">2549</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=29/18/2543"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">28.</span><a class="rev-xref-ref" href="#xref-ref-28-1" title="View reference 28. in text"
                           id="ref-28">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.28"
                             data-doi="10.1056/NEJMoa1214271">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Friboulet</span>
                                       <span class="cit-name-given-names">L</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Olaussen</span>
                                       <span class="cit-name-given-names">KA</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Pignon</span>
                                       <span class="cit-name-given-names">JP</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">ERCC1 isoform expression and DNA repair in non-small-cell lung cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">368</span>
                                 <span class="cit-issue">(12)</span>:<span class="cit-fpage"> 1101</span>–<span class="cit-lpage">1110</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1214271&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=23514287&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000316318600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">29.</span><a class="rev-xref-ref" href="#xref-ref-29-1" title="View reference 29. in text"
                           id="ref-29">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.29">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Fisher</span>
                                       <span class="cit-name-given-names">SB</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Fisher</span>
                                       <span class="cit-name-given-names">KE</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Patel</span>
                                       <span class="cit-name-given-names">SH</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and
                                    human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">119</span>
                                 <span class="cit-issue">(2)</span>:<span class="cit-fpage">454</span>–<span class="cit-lpage">462</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">30.</span><a class="rev-xref-ref" href="#xref-ref-30-1" title="View reference 30. in text"
                           id="ref-30">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.30"
                             data-doi="10.1056/NEJMoa1006448">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kwak</span>
                                       <span class="cit-name-given-names">EL</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Bang</span>
                                       <span class="cit-name-given-names">YJ</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Camidge</span>
                                       <span class="cit-name-given-names">DR</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">363</span>
                                 <span class="cit-issue">(18)</span>:<span class="cit-fpage">1693</span>–<span class="cit-lpage">1703</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1006448&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20979469&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000283546400004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">31.</span><a class="rev-xref-ref" href="#xref-ref-31-1" title="View reference 31. in text"
                           id="ref-31">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.31"
                             data-doi="10.1056/NEJMoa1002011">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Flaherty</span>
                                       <span class="cit-name-given-names">KT</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Puzanov</span>
                                       <span class="cit-name-given-names">I</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kim</span>
                                       <span class="cit-name-given-names">KB</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">363</span>
                                 <span class="cit-issue">(9)</span>:<span class="cit-fpage">809</span>–<span class="cit-lpage">819</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1002011&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=20818844&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000281196600004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">32.</span><a class="rev-xref-ref" href="#xref-ref-32-1" title="View reference 32. in text"
                           id="ref-32">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.32"
                             data-doi="10.1016/S1470-2045(14)70007-5">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Flaherty</span>
                                       <span class="cit-name-given-names">KT</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hennig</span>
                                       <span class="cit-name-given-names">M</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Lee</span>
                                       <span class="cit-name-given-names">SJ</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>. <span class="cit-pub-date">2014</span>;<span class="cit-vol">15</span>
                                 <span class="cit-issue">(3)</span>:<span class="cit-fpage">297</span>–<span class="cit-lpage">304</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(14)70007-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=24485879&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">33.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-107.11.djv253.33"
                             data-doi="10.1016/S0140-6736(12)60868-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hauschild</span>
                                       <span class="cit-name-given-names">A</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Grob</span>
                                       <span class="cit-name-given-names">JJ</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Demidov</span>
                                       <span class="cit-name-given-names">LV</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">380</span>
                                 <span class="cit-issue">(9839)</span>:<span class="cit-fpage">358</span>–<span class="cit-lpage">365</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(12)60868-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22735384&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000306842800033&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">34.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-107.11.djv253.34"
                             data-doi="10.1016/S1470-2045(11)70393-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Rosell</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Carcereny</span>
                                       <span class="cit-name-given-names">E</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Gervais</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive
                                    non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">13</span>
                                 <span class="cit-issue">(3)</span>:<span class="cit-fpage">239</span>–<span class="cit-lpage">246</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(11)70393-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=22285168&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000300880600031&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">35.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-107.11.djv253.35"
                             data-doi="10.1056/NEJMoa1214886">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Shaw</span>
                                       <span class="cit-name-given-names">AT</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kim</span>
                                       <span class="cit-name-given-names">DW</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Nakagawa</span>
                                       <span class="cit-name-given-names">K</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">368</span>
                                 <span class="cit-issue">(25)</span>:<span class="cit-fpage">2385</span>–<span class="cit-lpage">2394</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa1214886&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=23724913&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000320601700008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">36.</span><a class="rev-xref-ref" href="#xref-ref-36-1" title="View reference 36. in text"
                           id="ref-36">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.36"
                             data-doi="10.1158/1535-7163.MCT-12-0473">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Westin</span>
                                       <span class="cit-name-given-names">JR</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kurzrock</span>
                                       <span class="cit-name-given-names">R</span>
                                       </span>
                                    
                                 </li>
                              </ol><cite>. <span class="cit-article-title">It’s about time: lessons for solid tumors from chronic myelogenous leukemia therapy</span>. <abbr class="cit-jnl-abbrev">Mol Cancer Ther</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">11</span>
                                 <span class="cit-issue">(12)</span>:<span class="cit-fpage">2549</span>–<span class="cit-lpage">2555</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=molcanther&amp;resid=11/12/2549"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">37.</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37. in text"
                           id="ref-37">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.37"
                             data-doi="10.1200/JCO.2009.26.5983">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Von Hoff</span>
                                       <span class="cit-name-given-names">DD</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Stephenson</span>
                                       <span class="cit-name-given-names">JJ</span>
                                       <span class="cit-name-suffix">Jr</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Rosen</span>
                                       <span class="cit-name-given-names">P</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory
                                    cancers</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>
                                 <span class="cit-issue">(33)</span>:<span class="cit-fpage">4877</span>–<span class="cit-lpage">4883</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=28/33/4877"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">38.</span><a class="rev-xref-ref" href="#xref-ref-38-1" title="View reference 38. in text"
                           id="ref-38">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.38"
                             data-doi="10.1158/1078-0432.CCR-12-1627">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Tsimberidou</span>
                                       <span class="cit-name-given-names">AM</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Iskander</span>
                                       <span class="cit-name-given-names">NG</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hong</span>
                                       <span class="cit-name-given-names">DS</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">18</span>
                                 <span class="cit-issue">(22)</span>:<span class="cit-fpage">6373</span>–<span class="cit-lpage">6383</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=18/22/6373"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">39.</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference 39. in text"
                           id="ref-39">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.39"
                             data-doi="10.1093/annonc/mdt115">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Henary</span>
                                       <span class="cit-name-given-names">H</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hong</span>
                                       <span class="cit-name-given-names">DS</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Falchook</span>
                                       <span class="cit-name-given-names">GS</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">24</span>
                                 <span class="cit-issue">(8)</span>:<span class="cit-fpage">2158</span>–<span class="cit-lpage">2165</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=24/8/2158"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">40.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-107.11.djv253.40">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Hollebecque</span>
                                       <span class="cit-name-given-names">A</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Massard</span>
                                       <span class="cit-name-given-names">C</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">De Baere</span>
                                       <span class="cit-name-given-names">T</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Molecular screening for cancer treatment optimization (MOSCATO 01): A prospective molecular triage trial--Interim results</span>. <abbr class="cit-jnl-abbrev">ASCO Meeting Abstracts</abbr>. <span class="cit-pub-date">2013</span>;<span class="cit-vol">31</span>(<span class="cit-issue">15 Suppl</span>):<span class="cit-fpage">2512</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">41.</span><a class="rev-xref-ref" href="#xref-ref-41-1" title="View reference 41. in text"
                           id="ref-41">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.41"
                             data-doi="10.1158/1078-0432.CCR-12-0178">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Janku</span>
                                       <span class="cit-name-given-names">F</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Berry</span>
                                       <span class="cit-name-given-names">DA</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Gong</span>
                                       <span class="cit-name-given-names">J</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published
                                    between 2000 and 2009</span>. <abbr class="cit-jnl-abbrev">Clin Cancer Res</abbr>. <span class="cit-pub-date">2012</span>;<span class="cit-vol">18</span>
                                 <span class="cit-issue">(22)</span>:<span class="cit-fpage">6356</span>–<span class="cit-lpage">6363</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=clincanres&amp;resid=18/22/6356"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">42.</span><a class="rev-xref-ref" href="#xref-ref-42-1" title="View reference 42. in text"
                           id="ref-42">↵</a><div class="cit ref-cit ref-journal" id="cit-107.11.djv253.42">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Kopetz</span>
                                       <span class="cit-name-given-names">S</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Desai</span>
                                       <span class="cit-name-given-names">J</span>
                                       </span>
                                    
                                 </li>
                                 <li><span class="cit-auth">
                                       <span class="cit-name-surname">Chan</span>
                                       <span class="cit-name-given-names">E</span>
                                       </span>
                                    <span class="cit-etal">et al.</span>
                                    
                                 </li>
                              </ol><cite>
                                 <span class="cit-article-title">PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors</span>. <abbr class="cit-jnl-abbrev">ASCO Meeting Abstracts</abbr>. <span class="cit-pub-date">2010</span>;<span class="cit-vol">28</span>(<span class="cit-issue">15 Suppl</span>):<span class="cit-fpage">3534</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=ascomtg&amp;resid=28/15_suppl/3534"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/107/11/djv248.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/107/11/djv283.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/107/11.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2015) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    107
                                    </span><span class="slug-issue">
                                    (11):
                                    </span><span class="slug-elocation">
                                    
                                    djv253
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djv253" class="slug-doi">10.1093/jnci/djv253</span>
                                    </span>
                                 </cite>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/107/11/djv253.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/107/11/djv253.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/107/11/djv253/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-data">Supplementary Data</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=Meta-Analysis&amp;sortspec=date&amp;submit=Submit">Meta-Analysis</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;107/11/djv253" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B107%2F11%2Fdjv253&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/107/11/djv253.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=107/11/djv253&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/107/11/djv253.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjv253&amp;citation=Fontes%20Jardim%20et%20al.%20107%20%2811%29&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B107%2F11%2Fdjv253&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=26378224&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B107%2F11%2Fdjv253">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B107%2F11%2Fdjv253">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval%3A%20&amp;publicationDate=11%2F01%2F2015&amp;author=Denis%20L.%20Fontes%20Jardim%2C%20Maria%20Schwaederle%2C%20Caimiao%20Wei%2C%20J.%20Jack%20Lee%2C%20David%20S.%20Hong%2C%20Alexander%20M.%20Eggermont%2C%20Richard%20L.%20Schilsky%2C%20John%20Mendelsohn%2C%20Vladimir%20Lazar%2C%20Razelle%20Kurzrock&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjv253&amp;volumeNum=107&amp;issueNum=11&amp;startPage=&amp;endPage=&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/107/11/djv253.full?cited-by=yes&amp;legid=jnci;107/11/djv253#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/107/11/djv253" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/107/11/djv253?access_num=/jnci/107/11/djv253"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F107%2F11%2Fdjv253&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AFontes%20Jardim%20author%3AD.L.%22"
                              class="cb-art-gs-auth author-link">Articles by  Fontes Jardim, D. L.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AKurzrock%20author%3AR.%22"
                              class="cb-art-gs-auth author-link">Articles by  Kurzrock, R.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=26378224&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Fontes%20Jardim%20DL&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Fontes Jardim, D. L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Schwaederle%20M&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Schwaederle, M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Wei%20C&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Wei, C.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Lee%20JJ&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Lee, J. J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Hong%20DS&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Hong, D. S.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Eggermont%20AM&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Eggermont, A. M.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Schilsky%20RL&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Schilsky, R. L.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Mendelsohn%20J&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Mendelsohn, J.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Lazar%20V&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Lazar, V.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Kurzrock%20R&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Kurzrock, R.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="/content/107/11/djv253.full?related-urls=yes&amp;legid=jnci;107/11/djv253#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B107%2F11%2Fdjv253&amp;current-view-path=/content/107/11/djv253.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/107/11/djv253&amp;title=Impact%20of%20a%20Biomarker-Based%20Strategy%20on%20Oncology%20Drug%20Development%3A%20A%20Meta-analysis%20of%20Clinical%20Trials%20Leading%20to%20FDA%20Approval+--+Fontes%20Jardim%20et%20al.%20107%20%2811%29+--+jnci&amp;doi=10.1093/jnci/djv253&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-5">Methods</a></li>
                        <li><a href="#sec-9">Results</a></li>
                        <li><a href="#sec-16">Discussion</a></li>
                        <li><a href="#sec-17">Funding</a></li>
                        <li><a href="#notes-1">Notes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/107/11/djv253.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/107/11/djv253.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>